These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 23907740

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia.
    Riccobene TA, Khariton T, Knebel W, Das S, Li J, Jandourek A, Carrothers TJ, Bradley JS.
    J Clin Pharmacol; 2017 Mar; 57(3):345-355. PubMed ID: 27510635
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.
    Canut A, Isla A, Rodríguez-Gascón A.
    Int J Antimicrob Agents; 2015 Apr; 45(4):399-405. PubMed ID: 25700566
    [Abstract] [Full Text] [Related]

  • 5. A series of pharmacokinetic studies of ceftaroline fosamil in select populations: normal subjects, healthy elderly subjects, and subjects with renal impairment or end-stage renal disease requiring hemodialysis.
    Riccobene T, Jakate A, Rank D.
    J Clin Pharmacol; 2014 Jul; 54(7):742-52. PubMed ID: 24431097
    [Abstract] [Full Text] [Related]

  • 6. Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP).
    Guervil DJ, Kaye KS, Hassoun A, Cole P, Huang XY, Friedland HD.
    J Chemother; 2016 Jun; 28(3):180-6. PubMed ID: 25817579
    [Abstract] [Full Text] [Related]

  • 7. Population Pharmacokinetic Modeling and Probability of Target Attainment Analyses in Asian Patients With Community-Acquired Pneumonia Treated With Ceftaroline Fosamil.
    Li J, Das S, Zhou D, Al-Huniti N.
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):682-694. PubMed ID: 31044546
    [Abstract] [Full Text] [Related]

  • 8. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
    Lodise TP, Low DE.
    Drugs; 2012 Jul 30; 72(11):1473-93. PubMed ID: 22779432
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection.
    Casapao AM, Steed ME, Levine DP, Rybak MJ.
    Expert Opin Pharmacother; 2012 Jun 30; 13(8):1177-86. PubMed ID: 22594846
    [Abstract] [Full Text] [Related]

  • 11. Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections in obese patients.
    Evans JD, Udeani G, Cole P, Friedland HD.
    Postgrad Med; 2014 Sep 30; 126(5):128-34. PubMed ID: 25295657
    [Abstract] [Full Text] [Related]

  • 12. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Jorgenson MR, DePestel DD, Carver PL.
    Ann Pharmacother; 2011 Nov 30; 45(11):1384-98. PubMed ID: 22009993
    [Abstract] [Full Text] [Related]

  • 13. Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials.
    Corey GR, Wilcox MH, Gonzalez J, Jandourek A, Wilson DJ, Friedland HD, Das S, Iaconis J, Dryden M.
    Int J Antimicrob Agents; 2019 Jun 30; 53(6):830-837. PubMed ID: 30716446
    [Abstract] [Full Text] [Related]

  • 14. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia.
    Rank DR, Friedland HD, Laudano JB.
    J Antimicrob Chemother; 2011 Apr 30; 66 Suppl 3():iii53-9. PubMed ID: 21482570
    [Abstract] [Full Text] [Related]

  • 15. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.
    File TM, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley I, Thye D.
    Clin Infect Dis; 2010 Dec 15; 51(12):1395-405. PubMed ID: 21067350
    [Abstract] [Full Text] [Related]

  • 16. An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis.
    Sunzel M, Learoyd M, Li J, Li Y, Ngo N, Edeki T.
    Int J Antimicrob Agents; 2015 Dec 15; 46(6):682-8. PubMed ID: 26545441
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia.
    Bhavnani SM, Hammel JP, Van Wart SA, Rubino CM, Reynolds DK, Forrest A, Khariton T, Friedland HD, Riccobene TA, Ambrose PG.
    Antimicrob Agents Chemother; 2013 Dec 15; 57(12):6348-50. PubMed ID: 24041902
    [Abstract] [Full Text] [Related]

  • 19. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
    File TM, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley IA, Thye DA, FOCUS 1 investigators.
    J Antimicrob Chemother; 2011 Apr 15; 66 Suppl 3():iii19-32. PubMed ID: 21482566
    [Abstract] [Full Text] [Related]

  • 20. Ceftaroline fosamil for treatment of community-acquired pneumonia: findings from FOCUS 1 and 2 and potential role in therapy.
    DiMondi VP, Drew RH, Chen LF.
    Expert Rev Anti Infect Ther; 2011 Aug 15; 9(8):567-72. PubMed ID: 21819323
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.